First-in-class DLL3 confirms benefit as target’s pipeline expands

New data confirm that first-in-class DLL3 bispecific Imdelltra tarlatamab not only shrinks tumors in patients with essential-stage small cell lung cancer, but also helps them survive longer. The results validate DLL3 as a rare example of a successful new target for the challenging indication. At least five other companies presented on programs against the target at the American Society of Clinical Oncology conference in Chicago.

DLL3, an inhibitory ligand of the Notch signaling pathway, is highly expressed in neuroendocrine tumors and in about 85-96% of patients with SCLC — both are cancer types with high unmet need. ...